SH
Shukra Pharmaceuticals Ltd (SHUKRAPHAR)
₹84.16
Mkt cap
₹3,639 Cr
P/E ratio
82.10
P/B
31.29
Div yield
0.01%
ROE
28.90%
ROCE
37.00%
EPS (TTM)
₹1.03
Book value
₹3
52W range
40–85
Sector
Healthcare
Price history
Previous close
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing [1]
NSE SHUKRAPHARBSE 524632
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−0.75% from high₹84
₹40+110.08% from low₹85
Current
₹84.16
Prev close
₹82.22
Day
+2.36%
Price performance
1D
+2.41%
1W
+2.40%
1M
+34.66%
3M
+94.32%
6M
—
1Y
—
YTD
+103.19%
Financials
Revenue, profit & margin
P/E ratio
82.1×
SHUKRAPHAR is 142% above the sector median of 34.0×
SHUKRAPHAR82.1×
Sector median34.0×
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 11 | 13 | 5 | 6 | 39 | 6 | 24 | 44 | |
| YoY Sales growth | +270% | -52% | +336% | +652% | |||||
| Expenses | 7 | 6 | 4 | 6 | 12 | 6 | 4 | 26 | |
| Operating Profit | 4 | 7 | 1 | -0 | 27 | 1 | 19 | 19 | |
| OPM % | 37% | 55% | 24% | -7% | 69% | 11% | 81% | 42% | |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Profit before tax | 4 | 8 | 1 | 0 | 27 | 0 | 18 | 18 | |
| Tax % | 23% | 29% | 26% | -1,090% | 24% | 553% | 29% | 29% | |
| Net Profit | 3 | 5 | 1 | 2 | 20 | -2 | 13 | 13 | |
| EPS in Rs | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.29 | 0.29 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.04% · closed higher next day 1 of last 1
| Q2FY27 | |
|---|---|
| Broadcast | 4 Nov '26◦ |
| Earnings day | +0.04% |
| +1 day | +0.01% |
| +5 days | +2.95% |
| +15 days | — |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.16%Promoter
Promoters51.16%0.21
FIIs0.43%0.43
DIIs0.21%0.10
Public48.20%0.73
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,880.00 | 36.66 | 4,51,075 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,442.00 | 88.89 | 3,03,749 | 0.26% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,670.00 | 81.82 | 1,77,632 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,424.00 | 97.75 | 1,30,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,189.90 | 26.20 | 1,18,693 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,380.00 | 41.17 | 1,15,267 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,391.80 | 36.21 | 1,12,442 | 0.93% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Shukra Pharma. | ₹82.23 | 82.12 | 3,639 | 0.01% | 13 | +434.03% | 44 | +651.70% | 36.98% |
| Median: 160 Co. | ₹465.83 | 33.99 | 2,012 | 0.08% | 13 | +33.53% | 179 | +20.92% | 14.94% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 NovAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 5 Nov - Q2 FY27 revenue rose 652% to Rs44.20 crore; net profit increased to Rs16.01 crore.Reg 32 4 Nov - No deviation in utilization of Rs 10.46 crore preferential warrant proceeds for Q2 FY27.Unaudited Financial Results For The Quarter Ended 30Th September 2026 4 Nov - Board approved Q2/H1 FY27 results; name changed to Shukra Medtech, warrants converted.Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30Th September 2026 4 Nov - Board approved Q2/H1 FY27 results; name changed to Shukra Medtech and warrants converted.






